Academy

Jason Gotlib, MD - Update on Systemic Mastocytosis

Jason Gotlib, MD - Workup and Management of Eosinophilia in 2024 -

Andrew Kuykendall, MD - Of Rux, Ropeg and Rusfertide – Treatment of PV comes of age

Session 1 - Panel Discussion

Abdulraheem Yacoub, MD - What’s happening in ET in 2024

Lucia Masarova, MD - Current status of interferons in MPNs

Pankit Vachhani, MD - Early/pre-fibrotic PMF – Diagnosis, Prognosis and Management

Session 2 - Panel Discussion

Nikolai Podoltsev, MD - Making sense of all the prognostic models for MF

Ruben Mesa, MD - JAK inhibitors for MF – where we stand in 2024

Stephen T. Oh, MD - Management of Anemia in Myelofibrosis – Old and New Drugs

Session 3 - Panel Discussions

Prithviraj Bose, MD - Novel mechanisms of drug action in MF

Jeanne Palmer, MD - Allogeneic Stem Cell Transplantation for MF

Naveen Pemmaraju, MD - Moving Beyond Spleen and Symptoms: Time for New Endpoints in MF?

Session 4 - Panel Discussions

Mrinal Patnaik, MD - “Pre MDS” CHIP and CCUS

Sanam Loghavi, MD - Updates on MDS diagnosis and classification

Naval Daver, MD - Update on clinical trials in HR-MDS

Session 5 - Panel Discussions

Yazan Madanat, MD - Debate: Luspatercept is the new standard of care as first line therapy for LR-MDS - Yes

Maximilian Stahl, MD - Debate: Luspatercept is the new standard of care as first line therapy for LR-MDS - No

Debate Discussion

Amer Zeidan, MD - Measuring the clinical benefit of therapies in Lower and higher risk MDS

Michael R. Savona, MD - When and how to use Imetelstat for LR-MDS

Session 6 - Panel Discussion.